文献速递浆细胞疾病

基线循环肿瘤细胞联合PET/CT表现在不适合移植的多发性骨髓瘤中的分析

Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性研究纳入126例初诊不适合移植的多发性骨髓瘤(TIE-MM)患者,采用多参数流式细胞术定量循环克隆肿瘤细胞(CTC)并结合PET/CT计算总病灶糖酵解(TLG)。高CTC水平与更差的无进展生存(PFS)和总生存(OS)显著相关,高TLG水平同样与更差PFS和OS显著相关;基于CTC、TLG和R-ISS III构建的新模型可将患者分为3组,其中含全部危险因素组2年PFS为0%、5年OS为20%。

要点

  • 高CTC水平与显著更差的2年PFS(43.4% vs 68.1%,P < .001)和5年OS(39.0% vs 68.3%,P < .001)相关。
  • 高TLG水平与显著更差的2年PFS(41.2% vs 67.6%,P = .038)和5年OS(37.7% vs 63.1%,P = .019)相关。
  • 基于CTC、TLG和R-ISS III的新模型可分层,含全部危险因素组2年PFS为0%、5年OS为20%。

核心结论

  • 诊断时联合CTC与PET/CT容积评估可增强现有分层系统,并可能为风险适配治疗策略开辟道路。

研究设计与样本

  • 回顾性研究,纳入126例初诊不适合移植的多发性骨髓瘤(TIE-MM)患者,均接受多参数流式细胞术CTC定量和PET/CT检查,TLG采用Metavol软件计算。

主要发现

  • CTC中位百分比为0.06%(范围0%-4.82%),54例(42.9%)为高CTC水平。
  • 高CTC水平组2年PFS为43.4% vs 68.1%(P < .001),5年OS为39.0% vs 68.3%(P < .001)。
  • 高TLG水平组2年PFS为41.2% vs 67.6%(P = .038),5年OS为37.7% vs 63.1%(P = .019)。
  • 多因素分析显示R-ISS III、高CTC水平、高TLG水平和完全缓解是PFS和OS的显著预后因素。
  • 按危险因素数目分为3组,含全部危险因素组2年PFS为0%、5年OS为20%;无任何高危特征组2年PFS为78.6%、5年OS为79.5%。

关键数值与推荐

  • 高CTC水平定义为CTC中位百分比0.06%以上,54例(42.9%)患者符合。
  • 新预测模型使用CTC、TLG和R-ISS III三个危险因素进行分层。

临床怎么用

  • 作者认为诊断时联合CTC与PET/CT容积评估可增强现有分层系统,并可能为风险适配治疗策略开辟道路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to improve prognostic predictors in patients with transplant-ineligible multiple myeloma (TIE-MM) by combining baseline circulating clonal tumor cells (CTCs) and positron emission tomography/computed tomography (PET/CT) findings. The factors associated with prognosis were retrospectively investigated in 126 patients with TIE-MM who underwent CTC quantification by multiparameter flow cytometry and PET/CT at the initial presentation. The total lesion glycolysis (TLG) level was calculated using the Metavol software. The median percentage of CTC was 0.06% (range, 0%-4.82%), and 54 patients (42.9%) demonstrated high CTC levels. High CTC levels were associated with significantly poorer progression-free survival (PFS, 2-year 43.4% vs 68.1%; P < .001) and overall survival (OS, 5-year 39.0% vs 68.3%; P < .001). Similarly, high TLG levels significantly worsened the PFS (2-year, 41.2% vs 67.6%; P = .038) and OS (5-year, 37.7% vs 63.1%; P = .019). The multivariate analyses showed that Revised International Staging System (R-ISS) III, high CTC and TLG levels, and complete response were significant prognostic factors for PFS and OS. A novel predictive model was constructed using CTCs, TLG, and R-ISS III. The patients were stratified into 3 groups according to the number of risk factors, revealing an extremely high-risk group with a 2-year PFS of 0% and a 5-year OS of 20%. Patients without any high-risk features had better prognosis, with a 2-year PFS of 78.6% and a 5-year OS of 79.5%. The combination of CTCs and volumetric assessment of PET/CT at diagnosis augments the existing stratification systems and may pave the way for a risk-adapted treatment approach.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ikeda D, Terao T, Oura M, et al. Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma. Blood Adv. 2024. PMID: 38150271. doi:10.1182/bloodadvances.2023011890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。